CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: Human in vitro and in vivo studies and lack of CYP2D6 involvement

Xenobiotica

Volumn 34, Issue 10, 2004, Pages 875-887

  Somogyi, A A ^a   Menelaou, A ^a   Fullston, S V ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORZOXAZONE; COUMARIN; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROPROPOXYPHENE; FURAFYLLINE; KETOCONAZOLE; LANSOPRAZOLE; LIVER ENZYME; MEPHENYTOIN; NORDEXTROPROPOXYPHENE; OMEPRAZOLE; PROGUANIL; QUINIDINE; RECOMBINANT ENZYME; SULFAPHENAZOLE; TROLEANDOMYCIN;

ADULT; AGED; ARTICLE; CATALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER; MALE; MICROSOME; PROTEIN EXPRESSION;

ADMINISTRATION, ORAL; ADULT; AGED; CELLS, CULTURED; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; METHYLATION; MICROSOMES, LIVER; MIDDLE AGED; PHENOTYPE; PROPOXYPHENE;

EID: 10644287699     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250400008371     Document Type: Article

References (35)

1. ABERNETHY, D. R., GREENBLATT, D. J., MORSE, D. S. and SHADER, R. I., 1985, Interaction of propoxyphene with diazepam, alprazolam and lorazepam. British Journal of Clinical Pharmacology, 19, 51-57.
2. BERTZ, R. J. and GRANNEMAN, G. R., 1997; Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clinical Pharmacokinetics, 32, 210-258.
3. BRØSEN, K., GRAM, L. F., SCHOU, J., LARSEN, N. E. and THAYSSEN, P., 1985, Dextropropoxyphene kinetics after single and repeated oral doses in man. European journal of Clinical Pharmacology, 29, 79-84.
4. COLLER, J. K., SOMOGYI, A. A. and BOCHNER, F., 1997, Association between CYP2C19 genotype and proguanil oxidative polymorphism. British Journal of Clinical Pharmacology, 43, 659-660.
5. DUE, S. L., SULLIVAN, H. R. and McMAHON, R. E., 1976, Propoxyphene: pathways of metabolism in man and laboratory animals. Biomedical Mass Spectrometry, 3, 217-225.
6. EBERT, B., ANDERSEN, S., HJEDS, H. and DICKENSON, A. H., 1998, Dextropropoxyphene acts as a noncompetitive N-methyl-D-aspartate antagonist. Journal of Pain and Symptom Management, 15, 269-274.
7. ELONEN, E. and NEUVONEN, P. J., 1984, Mixed dextropropoxyphene poisoning: concentration-effect relationships and effect of naloxone. International Journal of Clinical Pharmacology and Therapeutic Toxicology, 22, 16-19.
8. FLANAGAN, R. J., JOHNSTON, A., WHITE, A. S. and CROME, P., 1989, Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage. British Journal of Clinical Pharmacology, 28, 463-469.
9. GAILLARD, Y. and PÉPIN, G., 1998, Gas chromatographic-mass spectrometric quantitation of dextropropoxyphene and nordextropropoxyphene in hair and whole blood after automated on-line solid-phase extraction application in twelve fatalities. Journal of Chromatography B, 709, 69-77.
10. GRUBER, C. M., MILLER, C. L., FINNERAN, J. and CHERNISH, S. M., 1956, The effectiveness of dextropropoxyphene hydrochloride and codeine phosphate as determined by two methods of clinical testing for relief of chronic pain. Journal of Pharmacology and Experimental Therapeutics, 118, 280-285.
11. HANSEN, B. S., DAM, M., BRANDT, J., HVIDBERG, E. F., ANGELO, H., CHRISTENSEN, J. M. and LOUS, P., 1980, Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man. Acta Neurologica Scandinavica, 61, 357-367.
12. HAWTON, K., SIMKIN, S. and DEEKS, J., 2003, Co-proxamol and suicide: a study of national mortality statistics and local non-fatal self poisonings. British Medical Journal, 326, 1006-1008.
13. HENTHORN, T. K., SPINA, E., DUMONT, E. and VON BAHR, C., 1989, In vitro inhibition of a polymorphic human liver P-450 isozyme by narcotic analgesics. Anesthesiology, 70, 339-342.
14. HUTCHINSON, M. R., MENELAOU, A., FOSTER, D. J., COLLER, J. K. and SOMOGYI, A. A., 2004, CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. British Journal of Clinical Pharmacology, 57, 287-297.
15. INABA, T., TYNDALE, R. E. and MAHON, W. A., 1986, Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo. British Journal of Clinical Pharmacology, 22, 199-200.
16. JAMES, H. M., COLLER, J. K., GILLIS, D., BAHNISCH, J., SALLUSTIO, B. C. and SOMOGYI, A. A., 2004, A new simple diagnostic assay for the identification of the major CYP2D6 genotypes by DNA sequencing analysis. International Journal of Clinical Pharmacology and Therapeutics (in press).
17. KERRY, N. L., SOMOGYI, A. A., BOCHNER, F. and MIKUS, G., 1994, The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes. British Journal of Clinical Pharmacology, 38, 243-248.
18. KIRKWOOD, L. C., NATION, R. L. and SOMOGYI, A. A., 1997, Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine. British Journal of Clinical Pharmacology, 44, 549-555.
19. KRANTZ, T., THISTED, B., STROM, J., ANGELD, H. R. and SORENSKN, M. B., 1986, Severe acute propoxyphene overdose: plasma concentrations of propoxyphene and norpropoxyphene and the effect of dopamine on circulatory failure. Acta Anaesthesiologica Scandinavica, 30, 271-276.
20. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measurement with the folin phenol reagent. Journal of Biological Chemistry, 193, 265-275.
21. MILLER, J. A., ROBBINS, E. B. and MEYERS, D. B., 1963, Antitussive activity of a series of dialkylaminodiphenylbutanol esters. Journal of Pharmaceutical Sciences, 52, 446-451.
22. MILLER, R. R., FEINGOLD, A. and PAXINOS, J., 1970, Propoxyphene hydrochloride. A critical review. Journal of the American Medical Association, 213, 996-1006.
23. NEWTON, D. J., WANG, R. W. and Lu, A. Y., 1995, Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154-158.
24. NICKANDER, R. C., EMMERSON, J. L., HYNES, M. D., STEINBERG, M. I. and SULLIVAN, H. R., 1984, Pharmacologic and toxic effects in animals of dextropropoxyphene and its major metabolite norpropoxyphene: a review. Human Toxicology, 3 (Suppl.), 13S-36S.
25. NICKANDER, R., SMITS, S. E. and STEINBERG, M. I., 1977, Propoxyphene and norpropoxyphene: pharmacologic and toxic effects in animals. Journal of Pharmacology and Experimental Therapeutics, 200, 245-253.
26. OMURA, T. and SATO, R., 1964, The carbon monoxide-binding pigment of liver microsomes. II. Solubilisation, purification and properties. Journal of Biological Chemistry, 234, 2374-2385.
27. PEARSON, R. M., 1984, Pharmacokinetics of propoxyphene. Human Toxicology, 3 (Suppl.), 37S-40S.
28. PETTERSSON, K. J. and NILSSON, L. B., 1992, Determination of dextropropoxyphene and norpropoxyphene in plasma by high-performance liquid chromatography. Journal of Chromatography, 581, 161-164.
29. ROBSON, R. A., MINERS, J. O., WHITEHEAD, A. G. and BIRKETT, D. J., 1987, Specificity of the inhibitory effect of dextropropoxyphene on oxidative drug metabolism in man: effects on theophylline and tolbutamide disposition. British Journal of Clinical Pharmacology, 23, 772-775.
30. SANZ, E. J. and BERTILSSON, L., 1990, d-Propoxyphene is a potent inhibitor of debrisoquine, but not S-mephenytoin 4-hydroxylation in vivo. Therapeutic Drug Monitoring, 12, 297-299.
31. SHIRAN, M. R., CHOWDRY, J., ROSTAMI-HODJEGAN, A., ELLIS, S. W., LENNARD, M. S., IQBAL, M. Z., LAGUNDOYE, O., SEIVENWRIGHT, N. and TUCKER, G. T., 2003, A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment. British Journal of Clinical Pharmacology, 56, 220-224.
32. SPINA, E., PISANI, F. and PERUCCA, E., 1996, Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clinical Pharmacokinetics, 31, 198-214.
33. WETLI, C. V. and BEDNARCZYK, L. R., 1980, Deaths related to propoxyphene overdose: a ten-year assessment. Southern Medical Journal, 73, 1205-1209.
34. YOUNG, R. J., 1983, Dextropropoxyphene overdosage. Pharmacological considerations and clinical management. Drugs, 26, 70-79.
35. ZANGER, U. M., VILBOIS, F., HARDWICK, J. P. and MEYER, U. A., 1988, Absence of hepatic cytochrome P450bufl causes genetically deficient debrisoquine oxidation in man. Biochemistry, 27, 5447-5454.